Latest ExpreS2ion Biotechnologies News & Updates
See the latest news and media coverage for ExpreS2ion Biotechnologies. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage vaccine biotechnology company
expres2ionbio.com- Headquarters
- Horsholm, Denmark
- Founded year
- 2010
- Company type
- Public company
- Number of employees
- 20–50
Last updated
Latest news about ExpreS2ion Biotechnologies
In short: ExpreS2ion Biotechnologies raised SEK 31.8 million in a rights issue to advance its HER2-positive breast cancer vaccine and malaria candidates.
Company announcements
-
ExpreS2ion announces final rights issue outcome
Subscription reached 59.9%, yielding SEK 31.8 million proceeds. Warrants could add equal amount if exercised.
-
ExpreS2ion Biotechnologies advances ES2B-C001 through phase I
Interim data expected over summer; phase I completion targets end of 2026. Rights issue remains open until April 30. Platform develops via partnerships.
-
ExpreS2ion highlights BIO-002 clinical data validating platform
Phase Ia study shows favorable safety, consistent antibody responses, and scalable dosing for malaria vaccine antigen produced with ExpreS2 platform. Supports partnered model and oncology pipeline.
-
ExpreS2ion Biotechnologies announces rights issue and clinical progress
CEO discusses Phase I advancement of ES2B-C001 in breast cancer, pipeline updates, and partnerships in interview. Proceeds fund development.
Media coverage
-
ExpreS2ion Biotech Holding AB: The Board of Directors of ExpreS2ion has resolved on a rights issue of units of approximately SEK 53 million, primarily to advance its lead ...
Hørsholm, Denmark, 7 April 2026 - The Board of Directors of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") has today, on 7 April...
-
ExpreS2ion reports consistent, durable anti-HER2 responses; advances ES2B-C001 Phase I after independent DSMB review — TradingView News
Hørsholm, Denmark, 25 March 2026 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of active...
-
ExpreS2ion Biotech Holding AB: EXPRES2ION ANNOUNCES THE BOARD OF DI...
Background and rationale ExpreS2ion is a biotechnology company focused on the development and application of advanced protein expression technologies for vaccines and immunotherapies targeting infectious...
-
Notice to convene Extraordinary General Meeting of ExpreS2ion Biotech Holding AB (publ) — TradingView News
The shareholders of ExpreS2ion Biotech Holding AB (publ), reg. no. 559033-3729 (the "Company"), are hereby invited to attend an extraordinary general meeting on 1 April...
Track ExpreS2ion Biotechnologies and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
ExpreS2ion Biotechnologies competitors & trending companies
Browse news for competitors to ExpreS2ion Biotechnologies and other trending companies.
Bavarian Nordic
Alligator Bioscience
Aura Biosciences
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable